European neurological review最新文献_第8页

How Can We Improve Current Practice in Spastic Paresis? 我们如何改进目前痉挛性麻痹的治疗?

European neurological review Pub Date : 2016-01-01 DOI: 10.17925/ENR.2016.11.02.79

K. Fheodoroff, J. Jacinto, A. Geurts, F. Molteni, Jorge Hernandez Franco, T. Santiago, R. Rosales, J. Gracies

{"title":"How Can We Improve Current Practice in Spastic Paresis?","authors":"K. Fheodoroff, J. Jacinto, A. Geurts, F. Molteni, Jorge Hernandez Franco, T. Santiago, R. Rosales, J. Gracies","doi":"10.17925/ENR.2016.11.02.79","DOIUrl":"https://doi.org/10.17925/ENR.2016.11.02.79","url":null,"abstract":"Spastic paresis can arise from a variety of conditions, including stroke, spinal cord injury, multiple sclerosis, cerebral palsy, traumatic brain injury and hereditary spastic paraplegia. It is associated with muscle contracture, stiffness and pain, and can lead to segmental deformity. The positive, negative and biomechanical symptoms associated with spastic paresis can significantly affect patients℉ quality of life, by affecting their ability to perform normal activities. This paper – based on the content of a global spasticity interdisciplinary masterclass presented by the authors for healthcare practitioners working in the field of spastic paresis – proposes a multidisciplinary approach to care involving not only healthcare practitioners, but also the patient and their family members/carers, and improvement of the transition between specialist care and community services. The suggested treatment pathway comprises assessment of the severity of spastic paresis, early access to neurorehabilitation and physiotherapy and treatment with botulinum toxin and new technologies, where appropriate. To address the challenge of maintaining patients℉ motivation over the long term, tailored guided self-rehabilitation contracts can be used to set and monitor therapeutic goals. Current global consensus guidelines may have to be updated, to include a clinical care pathway related to the encompassing management of spastic paresis.","PeriodicalId":12047,"journal":{"name":"European neurological review","volume":"11 1","pages":"79"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67592080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

Comorbidities Affecting Children with Epilepsy – Not a Novel Entity but New Insights Could Improve Holistic Care 影响癫痫儿童的合并症-不是一个新的实体，但新的见解可以改善整体护理

European neurological review Pub Date : 2016-01-01 DOI: 10.17925/ENR.2016.11.01.16

Tandokazi Quvile, J. Wilmshurst

引用次数: 1

Update on Extracranial Carotid Stenosis 颅外颈动脉狭窄的最新进展

European neurological review Pub Date : 2016-01-01 DOI: 10.17925/ENR.2016.11.01.18

T. Reiff, C. Gumbinger, S. Mundiyanapurath, P. Ringleb

引用次数: 1

Reaching Those Most in Need - A Call to Action for Advanced Parkinson's Disease. 帮助那些最需要帮助的人——呼吁对晚期帕金森病采取行动。

European neurological review Pub Date : 2016-01-01 DOI: 10.17925/ENR.2016.11.01.20

S. Agarwal, J. Fleisher

引用次数: 5

Post-mortem Magnetic Resonance Imaging as an Additional Tool of the Neuropathological Examination of Neurodegenerative and Cerebrovascular Diseases 死后磁共振成像作为神经退行性和脑血管疾病神经病理检查的附加工具

European neurological review Pub Date : 2016-01-01 DOI: 10.17925/ENR.2016.11.01.22

J. Reuck

引用次数: 5

Multi-stakeholder Colloquium – Opportunities and Challenges in Multiple Sclerosis Management 多方利益相关者研讨会-多发性硬化症管理的机遇与挑战

European neurological review Pub Date : 2016-01-01 DOI: 10.17925/ENR.2016.11.01.41

P. Vermersch, R. Gold, C. Holloway, À. Rovira, G. Giovannoni, M. Toumi

{"title":"Multi-stakeholder Colloquium – Opportunities and Challenges in Multiple Sclerosis Management","authors":"P. Vermersch, R. Gold, C. Holloway, À. Rovira, G. Giovannoni, M. Toumi","doi":"10.17925/ENR.2016.11.01.41","DOIUrl":"https://doi.org/10.17925/ENR.2016.11.01.41","url":null,"abstract":"In Europe, despite recent therapeutic advances, there are many deficiencies in the management of multiple sclerosis (MS). Diagnostic and monitoring measures, guidelines, development of new treatments and best practice care are often suboptimal. These shortcomings were discussed at two MS multi-stakeholder colloquia that were convened in Brussels, Belgium in May 2014 and May 2015, and gathered experts from a range of different specialities to identify the key issues and propose means of tackling them. After considering all the testimony and discussion, the organising committee drew up a list of 10 calls to action, which included: increase awareness and understanding in the EU about the burden of MS; obtain better insights into the direct and indirect cost burden of MS; (re)define treatment goals and clinical study endpoints; develop new tools to better capture the total clinical burden of MS; develop a protocol to standardise magnetic resonance imaging (MRI); develop biomarkers of treatment response prediction and disability progression; integrate drug licensing and cost-effectiveness decision-making processes; develop separate European Medicines Agency guidelines for evaluating follow-on products of non-biological complex drugs and biologicals; implement a set of evidence-based standards of care and incentives to support people with MS to remain physically and mentally active. Addressing these ambitious calls to action requires cooperation from various health bodies and governments and some will require additional funding, but they are achievable and worthwhile. They would help minimise disease impact and would reduce disease progression and the consequent burden on people with MS, their caregivers, and on health budgets. These calls to action set out a strategy for future MS management and should be acted upon with urgency.","PeriodicalId":12047,"journal":{"name":"European neurological review","volume":"11 1","pages":"41"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67591958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

European Academy of Neurology – What Has Happened Since the FirstConference in 2015 Conference in 2015? 欧洲神经病学学会-自2015年第一次会议以来发生了什么?

European neurological review Pub Date : 2016-01-01 DOI: 10.17925/ENR.2016.11.01.14

A. Sauerbier

引用次数: 0

Comprehensive Care of Patients with Spastic Paresis – A Long-Term Commitment 痉挛性麻痹患者的综合护理-一项长期承诺

European neurological review Pub Date : 2016-01-01 DOI: 10.17925/ENR.2016.11.01.1B

A. Ward, W. Jost, R. Jech, J. Gracies

{"title":"Comprehensive Care of Patients with Spastic Paresis – A Long-Term Commitment","authors":"A. Ward, W. Jost, R. Jech, J. Gracies","doi":"10.17925/ENR.2016.11.01.1B","DOIUrl":"https://doi.org/10.17925/ENR.2016.11.01.1B","url":null,"abstract":"Spastic paresis is a frequent complication of lesions to central motor pathways. Patients who develop spasticity require specialised rehabilitation programmes to alleviate their symptoms, help them to relearn motor skills and regain some independence. Long-term management of patients with spastic paresis requires a comprehensive approach that addresses the patient’s physical needs and mental wellbeing, and continues throughout all stages of the rehabilitation process. There are three pillars of success for long-term rehabilitation programmes in spastic paresis. Since most human behaviour is goal-directed, the first is to employ patient-centred goal setting to engage and motivate patients to play an active part in their own rehabilitation. Goals should be meaningful for and achievable by the patient, and revised as necessary. The second foundation of success is to ensure detailed clinical assessment, using appropriate spasticity assessment scales to inform Botulinum toxin treatment plans -doses and muscles to be injected. Lastly, the use of guided self-rehabilitation programmes encourages an active role for patients in their treatment and maximises outcomes. This paper summarises proceedings from the Comprehensive Care of Patients with Spastic Paresis: A Long-Term Commitment symposium, at the International Society of Physical and Rehabilitation Medicine World Congress, 2015.","PeriodicalId":12047,"journal":{"name":"European neurological review","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67591850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Physical Activity in Pediatric Multiple Sclerosis—Can Lifestyle Factors Affect Disease Outcomes? 儿童多发性硬化症的体育锻炼——生活方式因素会影响疾病结局吗?

European neurological review Pub Date : 2015-06-01 DOI: 10.17925/USN.2015.11.01.19

E. Yeh, R. Motl

引用次数: 0

Botulinum neurotoxin revisited – An individualised, patient-centric approach for the treatment of dystonia and spasticity 肉毒杆菌神经毒素重访-个体化，以患者为中心的方法治疗肌张力障碍和痉挛

European neurological review Pub Date : 2015-06-01 DOI: 10.17925/ENR.2015.10.01.28

M. Relja, J. Jacinto, J. Jankovic, A. Albanese

引用次数: 0